Invention Grant
- Patent Title: Optimization of enzyme replacement therapy for treatment of homocystinuria
-
Application No.: US17713891Application Date: 2022-04-05
-
Publication No.: US12042529B2Publication Date: 2024-07-23
- Inventor: Tomas Majtan , Jan P. Kraus , Erez M. Bublil , Frank Glavin , Marcia Sellos-Moura
- Applicant: THE REGENTS OF THE UNIVERSITY OF COLORADO , Travere Therapeutics Switzerland GmbH
- Applicant Address: US CO Denver
- Assignee: The Regents Of The University Of Colorado, A Body Corporate,Travere Therapeutics Switzerland GmbH
- Current Assignee: The Regents Of The University Of Colorado, A Body Corporate,Travere Therapeutics Switzerland GmbH
- Current Assignee Address: CO Denver; CH
- Agency: Seed IP Law Group LLP
- Main IPC: A61K38/51
- IPC: A61K38/51 ; A61K47/60 ; C12N9/88

Abstract:
The present invention provides a method of PEGylating a human truncated cystathionine β-synthase protein containing a mutation of a cysteine to a serine at amino acid position 15 (htCBS C15S). The htCBS C15S was PEGylated with one of 5 kDa, 10 kDa, or 20 kDa NHS ester PEG molecules. In-process monitoring of the PEGylation process was used in the method to reduce levels of unPEGylated htCBS C15S and htCBS C15S with insufficient PEGylation. Administration of the PEGylated htCBS C15S had efficacy throughout the course of treatment for homocystinuria.
Public/Granted literature
- US20230039591A1 OPTIMIZATION OF ENZYME REPLACEMENT THERAPY FOR TREATMENT OF HOMOCYSTINURIA Public/Granted day:2023-02-09
Information query
IPC分类: